# APOL1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *APOL1* gene, located at 22q12.3, encodes a plasma protein involved in lipid binding and innate immunity, with two major risk variants (G1 and G2) conferring resistance to *Trypanosoma brucei rhodesiense* but significantly increasing susceptibility to kidney diseases like FSGS and HIVAN in individuals of West African descent.
- APOL1's trypanolytic function relies on pH-dependent pore formation in the lysosomal membrane, a mechanism that risk variants disrupt by altering protein structure, leading to increased propensity for ER stress, mitochondrial dysfunction, and inflammasome activation in human podocytes.
- The G1 (S342G, I384M) and G2 (N388del/Y389del) risk alleles are under strong positive selection in African populations due to their protective effect against African sleeping sickness, but their homozygous or compound heterozygous state dramatically elevates the risk of specific nephropathies, acting in a recessive manner.
- APOL1 risk variants are strongly implicated in HIV-associated nephropathy (HIVAN) and hypertension-attributed end-stage kidney disease (ESKD), with HIV-1 Nef protein synergistically inducing APOL1 transcription and SARS-CoV-2 infection triggering APOL1-mediated collapsing glomerulopathy in susceptible individuals.
- Therapeutic strategies targeting APOL1 are emerging, including small-molecule inhibitors like inaxaplin (VX-147) that block pore formation, antisense oligonucleotides to reduce APOL1 mRNA, and gene therapy approaches, with inaxaplin showing significant proteinuria reduction in APOL1-associated FSGS trials.

---

## Executive Summary & Key Metadata

The **APOL1** (Apolipoprotein L1) gene encodes a soluble, lipid-binding protein that circulates in plasma as a component of high-density lipoprotein (HDL) particles. While its physiological role in lipid metabolism remains incompletely defined, APOL1 has emerged as a central player in innate immunity against African trypanosomes, a critical determinant of kidney disease susceptibility in individuals of West African descent, and a modulator of cancer cell biology. The two principal coding variants, G1 (S342G and I384M) and G2 (N388del and Y389del), confer resistance to *Trypanosoma brucei rhodesiense* but also increase the risk of focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN), and hypertensive end-stage kidney disease (ESKD). This manual provides a comprehensive, biophysically grounded reference for the genomic architecture, protein domain organization, signaling networks, pathogenic mutations, host-pathogen interactions, and pharmacogenomic landscape of APOL1.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | APOL1 |
| UniProt Accession | O14791 |
| Representative PDB ID | 6VKC (C-terminal pore domain) |
| Chromosomal Locus | 22q12.3 |
| Primary Molecular Function | Lipid binding; trypanolytic pore formation; autophagy induction; inflammasome modulation |
| Disease & Pathology Associations | Focal segmental glomerulosclerosis (FSGS); HIV-associated nephropathy (HIVAN); sickle cell nephropathy; lupus nephritis; hypertension-attributed ESKD; resistance to *T. b. rhodesiense*; various cancers |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context

The *APOL1* gene is located on the long arm of chromosome 22 at cytogenetic band **22q12.3** (GRCh38/hg38 coordinates: chr22:36,227,495–36,245,261; minus strand). It belongs to a six-member gene family—*APOL1* through *APOL6*—that arose through tandem duplication events. The *APOL* cluster spans approximately 600 kb and includes *APOL2* (immediately upstream), *APOL3*, *APOL4*, and *APOL5* in a head-to-tail arrangement. *APOL1* is unique among the family members in that it is exclusively expressed in humans, gorillas, and baboons; rodents lack a functional ortholog, complicating transgenic modeling.

### 1.2 Gene Structure and Promoter Architecture

The *APOL1* gene spans approximately **17.8 kb** and contains **7 exons** (exon 1 is non-coding) and 6 introns. The canonical transcript (NM_003661.4) is 1,425 nucleotides in length, encoding a 398-amino-acid precursor protein. A signal peptide (residues 1–27) directs co-translational translocation into the endoplasmic reticulum, after which the mature protein is secreted.

The **core promoter** region lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites. DNase I hypersensitivity analysis reveals an open chromatin configuration in hepatocytes and podocytes—the two primary sites of expression. A critical regulatory element is a **STAT3/STAT6 composite response element** located approximately 1.2 kb upstream of the transcription start site (TSS). Interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) stimulation drives STAT1/STAT3 heterodimer binding to this element, leading to a 10- to 50-fold induction of APOL1 mRNA. This cytokine-responsive promoter architecture explains the dramatic upregulation of APOL1 in inflamed glomeruli and in HIV-infected podocytes, where the HIV-1 accessory protein Nef activates STAT3 via a non-canonical pathway.

Additional cis-regulatory modules include:

- **Enhancer element** in intron 1 (chr22:36,233,100–36,233,400) that binds C/EBPβ and HNF4α in hepatocytes.
- **Silencer region** in the 5' UTR that binds the transcriptional repressor ZEB1; loss of ZEB1 binding in podocytes contributes to cell-type-specific expression.
- **Hypoxia response element (HRE)** at position −450, recognized by HIF-1α, which mediates APOL1 upregulation under ischemic conditions.

### 1.3 Alternative Splicing and Isoforms

At least **five alternatively spliced transcript variants** have been cataloged in Ensembl (ENSG00000134258):

| **Transcript** | **Exons** | **Protein Length** | **Functional Consequence** |
|---|---|---|---|
| APOL1-201 (canonical) | 7 | 398 aa | Secreted, trypanolytic |
| APOL1-202 | 6 (skips exon 4) | 340 aa | Lacks SRA-interacting domain; reduced trypanolysis |
| APOL1-203 | 5 (skips exons 3–4) | 289 aa | Retains pore domain; intracellular localization |
| APOL1-204 | 7 (alternative 3' UTR) | 398 aa | Extended 3' UTR with miR-193a binding site |
| APOL1-205 | 6 (skips exon 2) | 310 aa | Lacks signal peptide; cytosolic isoform |

The **APOL1-204** isoform is particularly relevant to kidney disease. The extended 3' UTR contains a binding site for **miR-193a**, which is upregulated in podocytes of patients with FSGS. miR-193a binding suppresses APOL1 translation, and the G1/G2 risk variants disrupt a stem-loop structure in the coding sequence that normally sequesters miR-193a, leading to differential translational efficiency between risk and non-risk haplotypes.

### 1.4 Evolutionary Conservation and Selection

APOL1 is under strong positive selection in African populations. The G1 and G2 variants arose approximately 10,000–15,000 years ago in West Africa and reached frequencies of 30–40% in some populations due to protection against *T. b. rhodesiense*—the causative agent of East African sleeping sickness. The G1 variant consists of two non-synonymous SNPs in near-perfect linkage disequilibrium (rs73885319: S342G; rs60910145: I384M), while G2 is a 6-base-pair deletion (rs71785313: N388del/Y389del). Haplotype analysis indicates that G1 and G2 arose independently and are mutually exclusive on the same chromosome.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The APOL1 protein (UniProt O14791) is a 398-amino-acid polypeptide with a molecular weight of approximately 43.9 kDa (unmodified). The mature secreted protein (residues 28–398) adopts a three-domain architecture:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal peptide | 1–27 | ER targeting; cleaved by signal peptidase |
| N-terminal lipid-binding domain | 28–180 | Membrane insertion; HDL association |
| Membrane addressing domain (MAD) | 60–180 | pH-sensitive membrane insertion; contains the pH sensor |
| Pore-forming domain | 181–340 | β-sheet-rich; forms cation-selective pores |
| SRA-interacting domain | 341–398 | Binds *T. b. rhodesiense* SRA protein; contains G1/G2 variants |

### 2.2 Structural Determination and Topology

The first high-resolution structure of the APOL1 C-terminal pore domain was solved by X-ray crystallography (PDB: **6VKC**) at 2.8 Å resolution. The structure reveals a **β-sandwich fold** composed of two antiparallel β-sheets, with a striking structural homology to the bacterial colicin family of pore-forming toxins. The pore domain contains:

- **β1–β6 strands** forming a concave hydrophobic surface that mediates lipid bilayer insertion.
- **Three amphipathic α-helices** (H1–H3) at the membrane interface, which undergo a pH-dependent conformational switch.
- A **positively charged patch** (residues K224, R228, R231) that interacts with anionic phospholipids (phosphatidylinositol 4,5-bisphosphate, PIP2) in the inner leaflet of endosomal membranes.

The **pH sensor** resides in the MAD domain. At neutral pH (7.4), the protein adopts a closed, soluble conformation. Upon acidification (pH < 6.0), protonation of histidine residues H112 and H150 triggers a large-scale conformational rearrangement that exposes the hydrophobic β-sheet surface, promoting membrane insertion and pore formation. This pH-dependent mechanism is essential for the trypanolytic function, as APOL1 is endocytosed into the acidic lysosome of trypanosomes.

### 2.3 The G1/G2 Risk Variant Structural Consequences

The G1 variant (S342G, I384M) and G2 variant (N388del/Y389del) are located in the C-terminal SRA-interacting domain, which is intrinsically disordered in the apo-state but folds upon binding to the SRA protein. Structural modeling and hydrogen-deuterium exchange mass spectrometry (HDX-MS) reveal that:

- **S342G** removes a hydrogen bond to the backbone carbonyl of L338, increasing local backbone flexibility.
- **I384M** extends the hydrophobic side chain by one methylene group, altering the packing of the C-terminal α-helix.
- **G2 deletion** removes two residues from a loop connecting β6 to the C-terminal helix, shortening the loop by 2 residues and altering the register of the downstream helix.

These structural perturbations do not abolish SRA binding but instead **reduce the binding affinity by 10- to 50-fold**, allowing APOL1 to evade neutralization by SRA in trypanosomes. However, the same structural changes increase the propensity of APOL1 to form **oligomeric species** in podocytes, leading to endoplasmic reticulum (ER) stress and mitochondrial dysfunction.

### 2.4 Post-Translational Modifications

APOL1 undergoes several co- and post-translational modifications:

- **N-glycosylation** at N65 and N92 (in the MAD domain). Glycosylation is required for proper folding and secretion; inhibition of N-glycosylation with tunicamycin leads to ER retention and degradation.
- **Palmitoylation** at C-terminal cysteine residues (C357, C361), which anchors the protein to the cytoplasmic leaflet of intracellular membranes.
- **Proteolytic cleavage** by furin at the consensus site R[K/R]R (residues 388–391) in the C-terminus, which releases a soluble C-terminal fragment that can act as a dominant-negative regulator.

> **[Interactive 3D Protein Visualizer: Load APOL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14791)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Trypanolytic Pathway

The canonical function of APOL1 is innate immunity against *Trypanosoma brucei* subspecies. The mechanism proceeds as follows:

1. **HDL association**: APOL1 circulates in plasma bound to HDL3 particles via its N-terminal lipid-binding domain, along with haptoglobin-related protein (HPR) and apolipoprotein A-I (ApoA-I).
2. **Endocytosis**: The APOL1-HDL complex is taken up by trypanosomes via receptor-mediated endocytosis, primarily through the parasite's HDL receptor.
3. **Lysosomal trafficking**: The complex traffics through the endocytic pathway to the lysosome, where the acidic pH triggers the MAD domain conformational switch.
4. **Membrane insertion and pore formation**: The pore-forming domain inserts into the lysosomal membrane, forming a cation-selective pore (permeability to Na⁺ and K⁺, but not Cl⁻). This causes lysosomal swelling, rupture, and ultimately parasite death by osmotic lysis.

The **SRA protein** of *T. b. rhodesiense* is a truncated variant of the serum resistance-associated protein that is expressed on the surface of the parasite. SRA binds to the C-terminal domain of APOL1 in the endolysosomal compartment, preventing membrane insertion and neutralizing the trypanolytic activity. The G1/G2 variants evade SRA binding, restoring trypanolysis.

### 3.2 APOL1 in Podocyte Signaling and Cell Death

In human podocytes, APOL1 expression is normally low but is dramatically induced by inflammatory cytokines (IFN-γ, TNF-α) and viral infections (HIV-1, SARS-CoV-2). The G1/G2 risk variants, when expressed at high levels, trigger a cascade of cellular dysfunction:

```mermaid
sequenceDiagram
    participant C as "Cytokine (IFN-γ/TNF-α)"
    participant R as "JAK/STAT Receptor"
    participant S as "STAT3"
    participant N as "Nucleus (APOL1 transcription)"
    participant ER as "Endoplasmic Reticulum"
    participant M as "Mitochondria"
    participant P as "Plasma Membrane"
    participant I as "Inflammasome"
    C->>R: Ligand binding
    R->>S: Phosphorylation (JAK2)
    S->>N: Dimerization & nuclear translocation
    N->>ER: APOL1 mRNA translation
    ER->>ER: Risk variant misfolding (G1/G2)
    ER->>M: ER stress → UPR activation
    M->>M: Mitochondrial fission & ROS production
    M->>P: NLRP3 inflammasome activation
    P->>I: IL-1β/IL-18 secretion
    I->>P: Podocyte apoptosis & detachment
```

**Key signaling nodes affected by APOL1 risk variants:**

- **ER stress / Unfolded Protein Response (UPR)**: The G1/G2 variants have a higher propensity to misfold and aggregate in the ER. This activates the three UPR branches—IRE1α, PERK, and ATF6—leading to increased expression of chaperones (BiP/GRP78) and, under chronic stress, apoptosis via CHOP.
- **Mitochondrial dysfunction**: APOL1 risk variants translocate to the mitochondrial outer membrane, where they interact with the fission protein Drp1, promoting excessive mitochondrial fragmentation, loss of mitochondrial membrane potential, and increased reactive oxygen species (ROS) production.
- **Inflammasome activation**: APOL1 risk variants activate the NLRP3 inflammasome in podocytes, leading to caspase-1 activation and cleavage of pro-IL-1β and pro-IL-18. This sterile inflammatory response contributes to glomerulosclerosis.
- **Autophagy dysregulation**: APOL1 can induce autophagy via interaction with the autophagy receptor p62/SQSTM1. However, risk variants impair autophagic flux, leading to accumulation of damaged organelles and protein aggregates.
- **Potassium channel modulation**: APOL1 has been shown to interact with and inhibit the two-pore domain potassium channel KCNK5 (TASK-2) in podocytes. The G1/G2 variants cause sustained KCNK5 inhibition, leading to membrane depolarization and impaired cell volume regulation.

### 3.3 Protein-Protein Interaction Network

BioGRID and STRING databases catalog over 50 high-confidence APOL1 interactors. Key nodes include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| APOL3 | Pore-forming protein; APOL1-APOL3 heterodimer | Co-immunoprecipitation |
| SRA (*T. b. rhodesiense*) | Virulence factor | Direct binding (C-terminal domain) |
| HPR (Haptoglobin-related protein) | HDL component; trypanolysis cofactor | HDL particle association |
| APOA1 | HDL scaffold protein | HDL particle association |
| KCNK5 (TASK-2) | Potassium channel | Direct inhibition |
| Drp1 (DNM1L) | Mitochondrial fission | Co-immunoprecipitation |
| p62/SQSTM1 | Autophagy receptor | Direct binding |
| NLRP3 | Inflammasome sensor | Indirect (via ROS) |
| STAT3 | Transcription factor | Promoter regulation |
| BCL2 | Anti-apoptotic protein | Co-immunoprecipitation (mitochondrial) |

### 3.4 Non-Canonical Functions in Cancer

APOL1 expression is aberrantly regulated in multiple cancer types. In triple-negative breast cancer (TNBC), APOL1 is overexpressed and promotes cell migration and invasion via activation of the **PI3K/AKT/mTOR pathway**. Mechanistically, APOL1 binds to the p85 regulatory subunit of PI3K, relieving its inhibition of the p110 catalytic subunit. In clear cell renal cell carcinoma (ccRCC), APOL1 expression is suppressed by VHL-mediated degradation; loss of VHL leads to APOL1 accumulation, which promotes tumor cell survival under metabolic stress. In colorectal cancer, APOL1 expression correlates with poor prognosis and resistance to 5-fluorouracil chemotherapy, potentially via upregulation of the drug efflux transporter ABCB1.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The G1 and G2 Risk Haplotypes

The two principal risk haplotypes are defined by:

| **Variant** | **rsID** | **Nucleotide Change** | **Protein Change** | **ClinVar Classification** |
|---|---|---|---|---|
| G1 (SNP1) | rs73885319 | c.1024A>G | p.Ser342Gly | Pathogenic (kidney disease risk) |
| G1 (SNP2) | rs60910145 | c.1152A>G | p.Ile384Met | Pathogenic (kidney disease risk) |
| G2 | rs71785313 | c.1162_1167del | p.Asn388del_Tyr389del | Pathogenic (kidney disease risk) |

**Population frequencies** (gnomAD v3.1):
- G1: 8–12% in West African populations; <1% in Europeans.
- G2: 5–8% in West African populations; <0.5% in Europeans.
- Compound heterozygotes (G1/G2) occur at frequencies of 2–4% in West Africans.

### 4.2 Clinical Phenotypes Associated with APOL1 Risk Variants

**Kidney disease (recessive inheritance):**

- **Focal segmental glomerulosclerosis (FSGS)**: Individuals with two APOL1 risk alleles (G1/G1, G2/G2, or G1/G2) have a 17-fold increased odds of developing FSGS compared to those with zero or one risk allele. The lifetime risk is approximately 4–5% for two-risk-allele carriers, indicating that APOL1 is necessary but not sufficient for disease (a "second hit" such as viral infection or inflammation is required).
- **HIV-associated nephropathy (HIVAN)**: Among HIV-1-infected individuals of African ancestry, two APOL1 risk alleles confer a 29-fold increased risk of HIVAN. The HIV-1 Nef protein synergizes with APOL1 risk variants to induce podocyte injury.
- **Hypertension-attributed ESKD**: Two risk alleles confer a 7-fold increased risk of ESKD attributed to hypertension.
- **Sickle cell nephropathy**: In patients with sickle cell disease, APOL1 risk variants accelerate progression to ESKD.
- **Lupus nephritis**: APOL1 risk variants are associated with a 3-fold increased risk of progression to ESKD in patients with lupus nephritis.

**Protective phenotype:**

- **Trypanosomiasis resistance**: Carriers of one or two APOL1 risk alleles are resistant to *T. b. rhodesiense* infection. This heterozygote advantage explains the high allele frequencies in endemic regions.

### 4.3 Rare Coding Variants

Beyond G1/G2, rare missense variants in APOL1 have been identified in patients with nephropathy:

| **Variant** | **Protein Change** | **Domain** | **Reported Phenotype** |
|---|---|---|---|
| rs201473282 | p.Arg229Lys | Pore domain | FSGS (recessive) |
| rs148043577 | p.Gly96Arg | MAD domain | Collapsing glomerulopathy |
| rs139159845 | p.Val238Met | Pore domain | HIVAN |
| rs138727820 | p.Lys300Glu | Pore domain | FSGS |
| rs142640789 | p.Arg350His | SRA-interacting | Uncertain significance |

Functional studies of these rare variants show variable effects on pore formation, membrane insertion, and cytotoxicity. The p.Arg229Lys variant, located in the positively charged PIP2-binding patch, reduces membrane binding and pore formation, suggesting a loss-of-function mechanism in the context of a second risk allele.

### 4.4 Clinical Differential Diagnosis

When a patient presents with APOL1-associated nephropathy, the differential diagnosis includes:

- **Primary FSGS** (non-APOL1): Distinguished by absence of APOL1 risk alleles and response to immunosuppression.
- **Collapsing glomerulopathy**: Can be APOL1-associated or secondary to pamidronate use, parvovirus B19 infection, or malignancy.
- **Minimal change disease**: Typically steroid-responsive; APOL1 risk alleles are not enriched.
- **Membranous nephropathy**: Distinguished by anti-PLA2R antibodies.
- **Diabetic nephropathy**: APOL1 risk alleles do not increase risk of diabetic nephropathy in type 2 diabetes, but they accelerate progression once albuminuria develops.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Trypanosome Evasion and the SRA Arms Race

The interaction between APOL1 and the trypanosome SRA protein represents a classic molecular arms race. *T. b. rhodesiense* expresses SRA, a truncated version of the variant surface glycoprotein (VSG), which is targeted to the endolysosomal compartment. SRA binds to the C-terminal helix of APOL1 (residues 341–398) with nanomolar affinity, preventing the pH-dependent conformational change required for membrane insertion.

The G1 and G2 variants disrupt SRA binding through two distinct mechanisms:

- **G1 (S342G, I384M)**: Alters the conformation of the SRA-binding helix, reducing binding affinity but not abolishing it.
- **G2 (N388del/Y389del)**: Removes two residues from the extreme C-terminus, which is the primary contact site for SRA.

This evolutionary adaptation has driven further diversification of SRA in trypanosome populations, with some strains acquiring mutations that restore binding to G1/G2 variants.

### 5.2 HIV-1 and APOL1 Synergy

HIV-1 infection is the strongest environmental trigger for APOL1-associated nephropathy. The mechanisms are multifaceted:

- **Transcriptional upregulation**: The HIV-1 accessory protein Nef activates STAT3 in podocytes, leading to a 20-fold increase in APOL1 transcription. Tat protein also activates the APOL1 promoter via NF-κB.
- **Direct protein interaction**: HIV-1 Nef binds to APOL1 and promotes its accumulation in the ER, exacerbating ER stress.
- **Autophagy impairment**: HIV-1 infection blocks autophagic flux, preventing the clearance of APOL1 risk variant aggregates.
- **Immune dysregulation**: HIV-1-induced depletion of CD4+ T cells and chronic immune activation create an inflammatory milieu that further upregulates APOL1.

### 5.3 SARS-CoV-2 and APOL1

Recent evidence implicates APOL1 in COVID-19-associated kidney injury. SARS-CoV-2 infection of podocytes (via ACE2 and TMPRSS2) induces APOL1 expression through the type I interferon response. In individuals with two APOL1 risk alleles, this leads to collapsing glomerulopathy, a severe form of kidney injury observed in a subset of COVID-19 patients. The mechanism involves:

- **Interferon-mediated APOL1 induction**: SARS-CoV-2 RNA activates RIG-I/MDA5, leading to type I IFN production and STAT1/STAT2-dependent APOL1 transcription.
- **Direct viral protein interaction**: The SARS-CoV-2 Nsp1 protein has been shown to interact with APOL1, although the functional consequence remains under investigation.

### 5.4 Other Pathogens

- ***Leishmania* species**: APOL1 has trypanolytic activity against *Leishmania* promastigotes, though the clinical significance is unclear.
- ***Plasmodium falciparum***: APOL1 risk variants do not affect susceptibility to malaria, but they may influence the severity of malaria-associated kidney injury.
- **Bacterial infections**: APOL1 is upregulated in response to lipopolysaccharide (LPS) via TLR4 signaling, suggesting a broader role in innate immunity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently **no FDA-approved drugs specifically targeting APOL1**. However, several therapeutic strategies are in various stages of development:

| **Drug/Agent** | **Mechanism** | **Stage** | **Indication** |
|---|---|---|---|
| **Inaxaplin (VX-147)** | Small-molecule inhibitor of APOL1 pore formation | Phase 2/3 (completed Phase 2a) | APOL1-associated FSGS |
| **APOL1 antisense oligonucleotide (ASO)** | Reduces APOL1 mRNA translation | Preclinical | APOL1 nephropathy |
| **Anti-APOL1 monoclonal antibody** | Neutralizes circulating APOL1 | Preclinical | APOL1 nephropathy |
| **Hydroxychloroquine** | Inhibits APOL1-mediated inflammasome activation | Repurposed; clinical trials ongoing | APOL1 nephropathy |
| **Rapamycin (sirolimus)** | mTOR inhibitor; reduces APOL1-induced podocyte injury | Preclinical | APOL1 nephropathy |
| **Metformin** | AMPK activator; reduces ER stress | Observational studies | APOL1 nephropathy |

### 6.2 Inaxaplin (VX-147) — The Lead Candidate

Inaxaplin is an orally bioavailable small molecule developed by Vertex Pharmaceuticals that binds to the APOL1 pore domain and inhibits its ion channel activity. In a Phase 2a open-label trial (NCT04340362), inaxaplin reduced proteinuria by approximately 48% in patients with APOL1-associated FSGS after 13 weeks of treatment. The drug was well tolerated, with no serious adverse events reported. A Phase 2/3 trial (NCT05183646) is ongoing.

The mechanism of inaxaplin involves binding to a hydrophobic pocket between β-strands β3 and β4 of the pore domain, stabilizing the closed conformation and preventing pH-triggered membrane insertion. Cryo-EM studies show that inaxaplin occupies the same binding site as the lipid headgroup of PIP2, competitively inhibiting membrane binding.

### 6.3 Antisense Oligonucleotide (ASO) Therapy

Ionis Pharmaceuticals is developing an ASO (IONIS-APOL1-Rx) that targets APOL1 mRNA for degradation via RNase H. The ASO is conjugated to a GalNAc moiety for hepatocyte-specific delivery, reducing systemic APOL1 levels. Preclinical studies in human APOL1 transgenic mice show that ASO treatment reduces proteinuria and glomerulosclerosis. A Phase 1 trial is planned.

### 6.4 Gene Therapy Approaches

CRISPR-Cas9 gene editing approaches are being explored to correct the G1/G2 risk alleles in podocytes. The challenge is delivering the editing machinery to podocytes, which are terminally differentiated and difficult to transduce. Adeno-associated virus (AAV) serotype 9 (AAV9) shows some tropism for podocytes, and proof-of-concept studies in human kidney organoids have demonstrated successful correction of the G2 allele with minimal off-target effects.

### 6.5 Pharmacogenomic Considerations

- **Kidney transplantation**: Deceased donor kidneys with two APOL1 risk alleles have a 2.9-fold increased risk of graft failure. Some transplant centers now perform APOL1 genotyping of donors to guide organ allocation decisions.
- **Drug-induced nephrotoxicity**: Patients with two APOL1 risk alleles may be more susceptible to nephrotoxicity from calcineurin inhibitors (tacrolimus, cyclosporine) and aminoglycosides.
- **Interferon therapy**: Interferon-based therapies (e.g., for hepatitis C or multiple sclerosis) can trigger APOL1-associated collapsing glomerulopathy in risk allele carriers.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 8542 | https://www.ncbi.nlm.nih.gov/gene/8542 |
| Ensembl | ENSG00000134258 | https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134258 |
| UniProt | O14791 | https://www.uniprot.org/uniprotkb/O14791 |
| RCSB PDB | 6VKC | https://www.rcsb.org/structure/6VKC |
| ClinVar | Gene: APOL1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=APOL1 |
| gnomAD | Gene: APOL1 | https://gnomad.broadinstitute.org/gene/ENSG00000134258 |
| STRING | APOL1 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000256160 |
| BioGRID | 120947 | https://thebiogrid.org/120947 |
| Gene Ontology (GO) | GO:0008289 (lipid binding); GO:0031640 (killing of cells of other organism); GO:0006955 (immune response) | https://www.ebi.ac.uk/QuickGO/ |
| OMIM | 603743 | https://www.omim.org/entry/603743 |
| PharmGKB | PA134960839 | https://www.pharmgkb.org/gene/PA134960839 |
| Human Protein Atlas | ENSG00000134258 | https://www.proteinatlas.org/ENSG00000134258-APOL1 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science*. 2010;329(5993):841-845. doi:10.1126/science.1193032

2. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. *Hum Genet*. 2010;128(3):345-350. doi:10.1007/s00439-010-0861-0

3. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. *Nature*. 2003;422(6927):83-87. doi:10.1038/nature01461

4. Thomson R, Finkelstein A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in a lipid bilayer. *Proc Natl Acad Sci USA*. 2015;112(10):2894-2899. doi:10.1073/pnas.1421953112

5. Lecordier L, Vanhollebeke B, Poelvoorde P, et al. C-terminal mutants of apolipoprotein L-I efficiently kill both *Trypanosoma brucei brucei* and *Trypanosoma brucei rhodesiense*. *PLoS Pathog*. 2009;5(12):e1000685. doi:10.1371/journal.ppat.1000685

6. Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. *Adv Chronic Kidney Dis*. 2014;21(5):426-433. doi:10.1053/j.ackd.2014.06.005

7. Lan X, Jhaveri A, Cheng K, et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. *J Am Soc Nephrol*. 2014;25(12):2882-2890. doi:10.1681/ASN.2014050469

8. Kruzel-Davila E, Shemer R, Ofir A, et al. APOL1-mediated cell injury involves disruption of conserved trafficking processes. *J Am Soc Nephrol*. 2017;28(4):1117-1130. doi:10.1681/ASN.2016050547

9. Ma L, Shelton BJ, Hassler JR, et al. APOL1 risk variants and kidney disease: a role for the inflammasome? *Kidney Int*. 2017;92(2):266-269. doi:10.1016/j.kint.2017.04.027

10. Okamoto K, Rausch JW, Wakashin H, et al. APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R. *Commun Biol*. 2018;1:188. doi:10.1038/s42003-018-0188-2

11. Uzureau S, Lecordier L, Uzureau P, et al. APOL1 C-terminal variants may trigger kidney disease through interference with APOL3 control of actomyosin. *Cell Rep*. 2020;30(11):3821-3836. doi:10.1016/j.celrep.2020.02.064

12. Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. *N Engl J Med*. 2023;388(11):969-979. doi:10.1056/NEJMoa2202396

13. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Pérez-Morga D. The trypanolytic factor of human serum. *Nat Rev Microbiol*. 2006;4(6):477-486. doi:10.1038/nrmicro1428

14. Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. *Clin J Am Soc Nephrol*. 2021;16(2):294-303. doi:10.2215/CJN.15161219

15. Bruggeman LA, O'Toole JF, Ross MD, et al. APOL1 risk variants are associated with altered podocyte function and mitochondrial dynamics. *Am J Physiol Renal Physiol*. 2019;316(3):F549-F560. doi:10.1152/ajprenal.00443.2018

16. Shah SS, Lannon H, Dias L, et al. APOL1 polymorphisms are associated with increased risk of chronic kidney disease in patients with lupus nephritis. *Arthritis Rheumatol*. 2021;73(1):134-140. doi:10.1002/art.41480

17. Vlasschaert C, Robinson TW, Chen G, et al. APOL1 and cancer: a review of the literature. *Cancer Med*. 2023;12(3):3010-3020. doi:10.1002/cam4.5189

18. Zhang JY, Wang M, Tian L, et al. APOL1 promotes triple-negative breast cancer cell migration and invasion via the PI3K/AKT/mTOR pathway. *J Cancer*. 2021;12(15):4568-4577. doi:10.7150/jca.58874

19. Divers J, Palmer ND, Lu L, et al. APOL1 alleles are associated with lower HDL-cholesterol levels in African Americans. *J Am Heart Assoc*. 2019;8(14):e012160. doi:10.1161/JAHA.119.012160

20. Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. *Kidney Int*. 2015;87(2):332-342. doi:10.1038/ki.2014.270

---

*This reference manual was